13 results about "Hyperalgesia" patented technology

To provide compounds and compositions for reducing most common opioid-induced hyperalgesia associated with microglial hyperactivation.SOLUTION: 2-pentadecyl-2-oxazoline (PEA-OXA) for use as an opioid adjuvant for preventing the development of or in the treatment of opioid-induced hyperalgesia (OIH), wherein the PEA-OXA is administered with or in combination with an opioid. Wherein the administration is separate, together or simultaneous.SELECTED DRAWING: None

2-Pentadecyl-2-oxazoline (also known as palmitoylethanolamide oxazoline or PEA-OXA) is used to counteract hyperalgesia induced by the most common opioids (OIH) associated with microglial hyperactivation. In particular, PEA-OXA is administered to humans and animals to prevent or treat some of the adverse effects of opioids by controlling immune hyperactivation. The PEA-OXA is administered separately, sequentially or jointly with the opioid.

The invention belongs to the technical field of animal-derived active polypeptides, and discloses a He-prescription crucian carp skin collagen peptide with anti-osteoarthritis activity and application thereof. After being subjected to in-vitro simulated digestion, the He-prescription crucian carp skin collagen peptide comprises 10 peptide fragments which are respectively LVGPPGLT, IGMPGMT, LIGPPGL, NIGMPGM, IGPGPI, LTGFPGAA, GFNGLPGS, MTGPIGL, VGPPGAP and GLPGLAGR. The invention also discloses that the combined-prescription crucian skin collagen peptide has anti-osteoarthritis activity, can be further used for preparing anti-osteoarthritis products, can obviously relieve hyperalgesia behaviors and anxiety depression behaviors caused by osteoarthritis of mice, and can obviously improve the defects of rough surface, serious abrasion and poor anti-osteoarthritis of knee joint cartilage of mice caused by osteoarthritis. The number of cartilage cells is reduced, and joint matrix protein is lost.

The present invention relates to use of botulinum toxin type E for preventing or treating neuropathic pain, and specifically, to a pharmaceutical composition comprising botulinum toxin type E for preventing or treating neuropathic pain, and a surgical operation analgesic comprising botulinum toxin type E as an active ingredient. The botulinum toxin type E of the present invention has an analgesic effect by significantly inhibiting neuropathic pain, and, after a single administration, the botulinum toxin type E of the present invention can alleviate side effects and provide an analgesic effect superior to that of Gabapentin, which is a conventional analgesic used for treating neuropathic pain, in mechanical allodynia caused by mandibular alveolar nerve injury. In addition, the botulinum toxin type E of the present invention has a short duration of analgesic action in the body after administration so as to enable faster recovery and rehabilitation than after administration of botulinum toxin type A, and thus can be effectively used for treatment of neuropathic pain.

The application discloses a kind of customized analgesic hydrogel and its preparation and application.Specifically, the application discloses a new analgesic target, screens suitable drugs, and according to the characteristics of drug molecules, two-step method is customized to obtain sustained-release analgesic hydrogel.The two-step method is specifically divided into the following: first, according to the structure of drug molecules, aldehyde-based hyaluronic acid is synthesized to realize chemical drug loading;Second, adjust the concentration of Schiff base to form a double grid environment to realize injectability.Load the inhibitory drug TAPI-1 for the new target ADAM17 of stomatognathic inflammatory pain, construct a drug delivery system with targeted delivery, sustained-release analgesia, local injection and long-acting effect.Compared with the prior art, the drug delivery system obtained by the application has excellent sustained-release performance, the prolonged drug release is consistent with the hyperalgesia window period of stomatognathic inflammatory pain, precise and effective pain management is achieved, and the operation is simple, and has good conversion application prospect.

The invention provides application of esketamine in preparation of hyperalgesia drugs, and relates to the technical field of clinical medicine. Clinical tests and animal experiments are combined, it is systematically proved that sub-anesthetic dose esketamine can effectively relieve diabetic hyperalgesia, and a novel molecular action mechanism of esketamine is disclosed. Preliminary tests and animal experiments show that the scheme can significantly improve the mechanical pain threshold and reduce the pain score, and the effect is exact. In mechanism, it is clarified for the first time that esketamine regulates and controls downstream PI3K / Akt / GSK-3beta signal channels by inhibiting excessive activation of an NMDA receptor, and abnormal expression and membrane transport of a GLuR1 receptor are reduced, so that central sensitization is reversed. The scheme has the advantages of quick response, no opioid drug dependence, clear mechanism and the like, provides a new safe, effective and clear-target analgesic strategy for clinical treatment of diabetes-related neuropathic pain, and has good transformation and application prospects.

This invention discloses the pharmaceutical use of schisandrin B in the preparation of analgesic drugs, wherein the analgesia is for the treatment or prevention of chemotherapy-induced neuropathic pain, and the analgesic drug can reduce mechanical and cold hyperalgesia in a chemotherapy-induced neuropathic pain model. Pharmacodynamic studies of this invention demonstrate that oral administration of schisandrin B can reduce chemotherapy-induced neuropathic pain, thereby effectively exerting an analgesic effect, and can be used as a therapeutic or preventative analgesic drug.

The application belongs to the technical field of animal-derived active polypeptides, and discloses a combined crucian carp skin collagen peptide with anti-osteoarthritis activity and application thereof. After in vitro simulation digestion, the combined crucian carp skin collagen peptide contains 10 peptide segments, which are LVGPPGLT, IGMPGMT, LIGPPGL, NIGMPGM, IGPGPI, LTGFPGAA, GFNGLPGS, MTGPIGL, VGPPGAP and GLPGLAGR. The combined crucian carp skin collagen peptide has anti-osteoarthritis activity, can be further used for preparing anti-osteoarthritis products, can significantly relieve the hyperalgesia behavior and anxiety and depression-like behavior of mice caused by osteoarthritis, and can significantly improve the rough surface of knee joint cartilage, serious wear, reduction of chondrocyte number and loss of joint matrix protein of mice caused by osteoarthritis.

The present invention relates to the treatment of endometriosis using an anti-Netrin-1 antibody or an antigen-binding fragment thereof, and to such an antibody or fragment thereof for use in treating endometriosis. The treatment includes reduction of endometriotic lesions, particularly uterine and / or uterine horn endometriotic lesions. The treatment further includes relief of chronic pelvic pain or vaginal hyperalgesia. This may also include reduction of colorectal hyperalgesia developed in endometriosis, improvement of bladder dysfunction developed in endometriosis, reduction of increased skin sensitivity to heat and / or mechanical stimuli developed in endometriosis, and improvement of overall health status altered by endometriosis.

The invention belongs to the technical field of biological medicines, and relates to an application of a Lin28b gene and an expression product thereof in preparation of a medicine for preventing or treating trigeminal nerve injury oral-maxillofacial pain, in particular to a medicine for preventing or treating suborbital nerve compression injury. In a trigeminal nerve injury model, the expression of the Lin28b in trigeminal ganglion (TG) and the expression of the Lin28b in the spinous tract nucleus (Sp5) are obviously up-regulated, the expression of the Lin28b in the trigeminal ganglion (Sp5) is obviously up-regulated, and the expression of the Lin28b in the trigeminal tract nucleus (Sp5) is obviously up-regulated. By up-regulating the expression of Lin28b or activating the protein function of Lin28b, the oral and maxillofacial mechanical hyperalgesia behavior of a model animal can be effectively relieved; the invention provides a siRNA (small interfering ribonucleic acid), shRNA (short hairpin ribonucleic acid), CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats) gene editing system, a specific antibody or a small-molecule inhibitor and the like which take the Lin28b gene as a target spot, and is used for developing a novel medicine for treating the stomatomaxillofacial neuropathic pain.

The present application relates to a kind of extracellular vesicle compositions and its preparation method and use, specifically relates to a kind of extracellular vesicle compositions in preparation for the use of drug for preventing and / or treating pain hyperalgesia and / or promoting wound healing, the active ingredients of the extracellular vesicle composition include mesenchymal stem cell-derived extracellular vesicle and lidocaine.The present application can achieve the double goal of "promoting wound healing" and "preventing pain hyperalgesia caused by scald, pain hyperalgesia", fundamentally improve the long-term prognosis of infant scald patient.

The invention provides a preparation process and application of high-purity epalrestat, and belongs to the technical field of medicines. Glycine, sodium chloroacetate, alpha-methylcinnamyl aldehyde and the like are used as starting materials, an epalrestat crude product is prepared through the steps of addition, substitution ring closing, condensation and the like, and then epalrestat with the purity larger than or equal to 99.0% is obtained through hydrochloric acid-acetic acid water solution backflow and methanol-tetrahydrofuran mixed solvent crystallization refining. According to the present invention, the condensation reaction temperature is controlled at 60-90 DEG C, the condensation reaction time is 1-3 h, the cooling speed is 0.2-0.5 DEG C / min during refining until the temperature is reduced to 10-30 DEG C, crystallization is performed, and the crystallization solvent is added, such that the epalrestat purity is significantly improved. Animal experiments show that the epalrestat prepared by the invention can effectively reduce blood sugar and improve hyperalgesia in a diabetic peripheral neuropathy rat model, is suitable for treating the disease, can be used for preparing tablets, and has a good clinical application prospect.

The present application relates to a kind of target extraction process of inducing mesenchymal stem cell secretion TGF-β and IL-10 anti-inflammatory factor combination and its application in pain treatment preparation, the process is activated mesenchymal stem cell by VEGF-A-link-TNF-α fusion protein as shown in SEQ ID NO:4 Specific, significantly improve its TGF-β and IL-10 secretion level;The fusion protein is targeted with TNF-α inflammatory signal by VEGF receptor cooperation, realize the efficient induction of anti-inflammatory factor expression;Mesenchymal stem cell pretreated by VEGF-A-link-TNF-α fusion protein as shown in SEQ ID NO:4 can significantly relieve the hyperalgesia of neuropathic pain model, with significant clinical application prospect.